SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen depri
SAN FRANCISCO— Four out of ten patients whose metastatic castration resistant prostate cancer had already been treated with abiraterone responded to further ‘new generation’ androgen deprivation therapy — with enzalutamide — with a PSA decline of at least 30 per cent. Heather H Cheng MD PhD, who is a Senior Reseach Fellow at the Fred Hutchinson Cancer Research Center in Seattle, Washington, presented her results at a poster session of the 2014 ASCO Genitourinary Cancers Symposium.
CONTACT:
Heather H Cheng MD PhD
Senior Reseach Fellow
Fred Hutchinson Cancer Research Center
Seattle, Washington 98109
SOURCE:
2014 ASCO Genitourinary Symposium, San Francisco
Abstract 18
“The effect of prior abiraterone use on the activity of enzalutamide in men with mCRPC”
ABSTRACT LINK:
http://meetinglibrary.asco.org/content/124184-142
Tags
Related Episodes
Enzalutamide improves overall and progression-free survival in men with chemotherapy-naïve metastatic castration-resistant prostate cancer
SAN FRANCISCO— The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metast
Initial Gleason score does not predict abiraterone response in patients with metastatic castration-resistant prostate cancer
SAN FRANCISCO— Gleason score at initial diagnosis was not predictive of response to abiraterone in patients with metastatic castration-resistant prostate cancer in a pooled analysis of three trials of
Orteronel shows no survival advantage in metastatic castration-resistant prostate cancer: phase III randomized study finds
SAN FRANCISCO—Orteronel — a non-steroidal selective inhibitor of 17,20-lyase — did not achieve a significant improvement in overall survival in 1099 patients randomised to treatment with this “a